The agency has recommended approval of Comirnaty and Spikevax for children from six months of age.
The European Medicines Agency announced on Oct. 19, 2022 that its Committee for Medicinal Products for Human Use (CHMP) has recommended approval of COVID-19 vaccines that target the original strain of SARS-CoV-2 for children aged six months to four years old for Comirnaty and six months to five years for Spikevax. Both vaccines are approved for adults and children ages five and up for Comirnaty and six and up for Spikevax.
According to EMA, the dosage of these vaccines will be lower in the younger age groups. Comirnaty will be given in three doses (of 3 micrograms each) with the first two doses given three weeks apart and the third dose given at least eight weeks after the second dose. Spikevax’s dosage for the younger age group will be two doses (of 25 micrograms each), given four weeks apart.
A study showed that Comirnaty had a comparable immune response at the lower dose in young children compared with the higher dose of 30 micrograms in people ages 16–25. Another study showed that Spikevax’s lower dose for young children was comparable to the higher dose of 100 micrograms in 18–25-year-olds. Side effects were also comparable to the older age groups.
“The CHMP therefore concluded that the benefits of Comirnaty and Spikevax in children aged from 6 months to 4 and 5 years, respectively, outweigh the risks. The safety and efficacy of both vaccines, in children and adults, will continue to be monitored closely as they are used in vaccination campaigns in EU [European Union] Member States through the EU pharmacovigilance system and ongoing and additional studies conducted by the company and coordinated by European authorities,” the agency stated in a press release.
CHMP’s recommendation will be sent to the European Commission for final decision applicable to EU Member States.
Source: EMA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.